Dianlong Jia, Shiqi Zhao, Huimin Liu, Xinyu Zhan, Zhongxia Zhou, Mingjia Lv, Xiufeng Tang, Wen Guo, Hui Li, Lilan Sun, Yidong Zhong, Baoqing Tian, Dandan Yuan, Xiaohui Tang, Qing Fan
In clinical practice, tumor-targeting diagnosis and immunotherapy against programmed death ligand 1 (PD-L1) have a significant impact. In this research, a PD-L1-antagonistic affibody dimer (ZPD-L1 ) was successfully prepared through Escherichia coli expression system, and conjugated with the photosensitizer of ICG via N-hydroxysuccinimide (NHS) ester to develop a novel tumor-targeting agent (ICG-ZPD-L1 ) for both tumor imaging diagnosis and photothermal-immunotherapy simultaneously. In vitro, ZPD-L1 could specifically bind to PD-L1-positive LLC and MC38 tumor cells, and ICG-ZPD-L1 -mediated photothermal therapy (PTT) also showed excellent phototoxicity to these tumor cells...
May 2, 2024: International Journal of Biological Macromolecules